Cite
HARVARD Citation
Panaccione, R. et al. (n.d.). S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study. American journal of gastroenterology. p. S348. [Online].